This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 25
-Paragraph 23
-URI https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460

+ Details

Name:	us-gaap_BusinessCombinationAcquisitionRelatedCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

+ Details

Name:	us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 730
-Section 25
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Value of new stock classified as temporary equity issued during the period.

+ References

No definition available.

+ Details

Name:	us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Contingent Milestone Obligation Accrued

+ References

No definition available.

+ Details

Name:	vera_ContingentMilestoneObligationAccrued
Namespace Prefix:	vera_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

License and collaborations.

+ References

No definition available.

+ Details

Name:	vera_LicenseAndCollaborationsLineItems
Namespace Prefix:	vera_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Milestone payments paid.

+ References

No definition available.

+ Details

Name:	vera_MilestonePaymentsPaid
Namespace Prefix:	vera_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone payments payable.

+ References

No definition available.

+ Details

Name:	vera_MilestonePaymentsPayable
Namespace Prefix:	vera_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Reduction In Contingent Future Development

+ References

No definition available.

+ Details

Name:	vera_ReductionInContingentFutureDevelopment
Namespace Prefix:	vera_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Stock issued during period shares licensing payments in equity.

+ References

No definition available.

+ Details

Name:	vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity
Namespace Prefix:	vera_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Stock Issued During Period Shares Licensing Payments In Equity (value)

+ References

No definition available.

+ Details

Name:	vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquityValue
Namespace Prefix:	vera_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Temporary Equity Issue Price Per Share.

+ References

No definition available.

+ Details

Name:	vera_TemporaryEquityIssuePricePerShare
Namespace Prefix:	vera_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Temporary equity stock shares issued during the period shares.

+ References

No definition available.

+ Details

Name:	vera_TemporaryEquityStockSharesIssuedDuringThePeriodShares
Namespace Prefix:	vera_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	vera_AgreementAxis=vera_AresAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vera_AresTradingSAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	vera_EventAxis=vera_AchievementOfSpecifiedBlaFilingOrRegulatoryApprovalMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	vera_EventAxis=vera_AchievementOfSpecifiedCommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	vera_AgreementAxis=vera_AmplyxAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vera_AmplyxAndNovartisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	vera_EventAxis=vera_AchievementOfVariousClinicalDevelopmentAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	vera_AgreementAxis=vera_NovartisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=vera_SeriesCRedeemableConvertiblePreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Licenses and Collaborations - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands		9 Months Ended	12 Months Ended
	Oct. 31, 2020	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
License And Collaborations [Line Items]
Research and development			$ 68,993	$ 22,484
Ares Agreement [Member] \| Ares Trading S A [Member]
License And Collaborations [Line Items]
Milestone payments paid					$ 25,000
Related party transaction, expenses from transactions with related party			4,500	1,700
Ares Agreement [Member] \| Ares Trading S A [Member] \| Achievement Of Specified BLA Filing Or Regulatory Approval Milestones [Member]
License And Collaborations [Line Items]
Milestone payments payable					$ 176,500
Ares Agreement [Member] \| Ares Trading S A [Member] \| Achievement Of Specified Commercial Milestones [Member]
License And Collaborations [Line Items]
Milestone payments payable						$ 515,000
Amplyx Agreement [Member]
License And Collaborations [Line Items]
Milestone payments payable				2,000
Acquisition cost				5,000
Research and development			3,700	7,000
Reduction in contingent future development			7,000
Contingent milestone obligation accrued				$ 2,000
Issuance of common stock for payment of licensing fees in equity, net of offering cost			5,700
Amplyx Agreement [Member] \| Amplyx and Novartis [Member] \| Achievement of Various Clinical Development and Regulatory Milestones [Member]
License And Collaborations [Line Items]
Milestone payments payable			7,000
Novartis [Member] \| Amplyx and Novartis [Member] \| Achievement of Various Clinical Development and Regulatory Milestones [Member]
License And Collaborations [Line Items]
Milestone payments payable			$ 62,000
Series C [Member] \| Ares Agreement [Member] \| Ares Trading S A [Member]
License And Collaborations [Line Items]
Initial fee paid as consideration	22,171,553
Temporary equity purchase price per share	$ 0.5918
Temporary equity shares issued during the period value	$ 13,100
Common Class A [Member]
License And Collaborations [Line Items]
Issuance of common stock for payment of licensing fees, net of offering costs, shares		283,034	283,034